Stay updated on Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial page.

Latest updates to the Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial page
- CheckyesterdayChange DetectedThe page has undergone significant content removal, particularly regarding a Phase 1b/2a clinical study for a HPV vaccine and its associated details, while a new revision number has been added.SummaryDifference10%
- Check8 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check16 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check23 days agoNo Change Detected
- Check52 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.9%
- Check66 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for the Help Desk.SummaryDifference0.9%
- Check73 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial page.